NCT00676299View on ClinicalTrials.gov

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2006

Study Completion Date

July 31, 2008

Conditions
Protein Kinase InhibitorsAntineoplastic ProtocolsClinical Trial, Phase 1Maximum Tolerated DosePharmacokineticsAdvanced MalignanciesSolid Malignancies
Interventions
DRUG

JNJ-26483327

All Listed Sponsors
collaborator

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00676299 - A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | Biotech Hunter | Biotech Hunter